Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Haubrich

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Medical Mycology|April 17, 2008
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitisEric Milefchik, Mary Ann Leal, Richard Haubrich, et al.
ACR Open Rheumatology|March 2, 2024
Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced TherapyJeffrey R Curtis, Robert R McLean, I-Heng Lee, et al.
AIDS Patient Care and Stds|May 9, 2019
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with MenJill Blumenthal, David J Moore, Sonia Jain, et al.
Antimicrobial Agents and Chemotherapy|March 25, 2009
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapyJoseph J Eron, Jeong-Gun Park, Richard Haubrich, et al.
AIDS Research and Human Retroviruses|May 9, 2008
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infectionJeffrey A Anderson, Hongyu Jiang, Xiao Ding, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359Courtney V Fletcher, Marcia A Testa, Richard C Brundage, et al.
AIDS (London, England)|April 7, 2007
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patientsRichard Haubrich, Dan Berger, Philippe Chiliade, et al.
Antiviral Therapy|November 3, 2010
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsChristine Katlama, Bonaventura Clotet, Anthony Mills, et al.
Plos One|January 26, 2018
Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adultsMary F Kearney, Jonathan Spindler, Ann Wiegand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
A practical method to calibrate self-reported adherence to antiretroviral therapyHonghu Liu, Loren G Miller, Ron D Hays, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Medical Mycology|April 17, 2008
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitisEric Milefchik, Mary Ann Leal, Richard Haubrich, et al.
ACR Open Rheumatology|March 2, 2024
Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced TherapyJeffrey R Curtis, Robert R McLean, I-Heng Lee, et al.
AIDS Patient Care and Stds|May 9, 2019
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with MenJill Blumenthal, David J Moore, Sonia Jain, et al.
Antimicrobial Agents and Chemotherapy|March 25, 2009
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapyJoseph J Eron, Jeong-Gun Park, Richard Haubrich, et al.
AIDS Research and Human Retroviruses|May 9, 2008
Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infectionJeffrey A Anderson, Hongyu Jiang, Xiao Ding, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359Courtney V Fletcher, Marcia A Testa, Richard C Brundage, et al.
AIDS (London, England)|April 7, 2007
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patientsRichard Haubrich, Dan Berger, Philippe Chiliade, et al.
Antiviral Therapy|November 3, 2010
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsChristine Katlama, Bonaventura Clotet, Anthony Mills, et al.
Plos One|January 26, 2018
Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adultsMary F Kearney, Jonathan Spindler, Ann Wiegand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
A practical method to calibrate self-reported adherence to antiretroviral therapyHonghu Liu, Loren G Miller, Ron D Hays, et al.
Pageof 11